Meeting highlights from the Committee forMedicinal Products for Human Use (CHMP)21-24 March 2022
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-march-2022
EMA EudraVigilance Registration Manual
https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/eudravigilance-registration-manual_en.pdf
EMA Management Board: highlights of March 2022 meeting
https://www.ema.europa.eu/en/news/ema-management-board-highlights-march-2022-meeting
PRAC recommendations on safety signals
https://www.ema.europa.eu/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-february-2022-prac-meeting_en.pdf
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 March 2022
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-march-2022
CTIS Training Programme – Module 09
https://www.ema.europa.eu/documents/other/step-step-guide-how-search-view-download-clinical-trial-clinical-trial-application-sponsors-ctis_en.pdf
EudraVigilance – EVWEB User Manual
https://www.ema.europa.eu/documents/regulatory-procedural-guideline/eudravigilance-evweb-user-manual-version-16_en.pdf
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022
List of medicines under additional monitoring – February 2022 – EMA
https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring/list-medicines-under-additional-monitoring